Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
TEL AVIV, July 31 (Reuters) - Israel's Pluristem Therapeutics Inc reported on Wednesday positive results from a series of studies in animals of its placenta-based stem cell therapy to treat acute radiation syndrome (ARS).
The studies were conducted by the U.S. Department of Defenses Armed Forces Radiobiology Research Institute.
The tests, conducted via the Food and Drug Administration's "animal rule pathway" as ARS cannot be tested in humans, were designed to evaluate Pluristem's PLX-R18 as a preventative treatment for ARS before radiation exposure.
The studies demonstrate that PLX-R18, administered 24 hours before radiation exposure and again 72 hours after exposure, resulted in an increase in survival rates of 46-70% compared with the control group, Pluristem said.
The data also showed an increase in recovery of blood platelets, neutrophils, white blood cells and lymphocytes and a favourable safety profile. Analysis of tissues collected showed an increase in bone marrow cell numbers and improved regenerative capability, the company said.
"We believe that this outcome is an important contribution to protect the armed and medical forces which may need to enter contaminated areas," Chief Executive Officer Yaky Yanay said.
"It is Pluristems goal to provide the different federal agencies access to PLX-R18 that it may be used as a countermeasure both before and after radiation exposure in order to minimize haematological and other organ damage."
The Department of Defense is conducting further studies.
PLX-R18 is also being evaluated by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, as a treatment following radiation exposure.
Last year, the FDA cleared the emergency use of Pluristem's therapy to treat ARS in a nuclear event. (Reporting by Tova Cohen; Editing by Steven Scheer and Mark Potter)